Oncopeptides AB

As of June 30, 2026, Oncopeptides AB carries a market capitalization of 55.75M, placing it among publicly traded companies globally. Its enterprise value stands at 53.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Oncopeptides AB's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Oncopeptides AB has 381.36M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.99, and the price-to-book ratio stands at 24.77.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 53.73M versus a market cap of 55.75M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Oncopeptides AB maintains a current ratio of 3.78, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -118.82, reflecting losses generated across the asset base. The company generates approximately 118,222.34 in revenue per employee across its workforce of 72.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.36 indicates how many times Oncopeptides AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Oncopeptides AB recorded 140,118.49 in income tax expense. The company reported a pretax loss of -19.09M and -19.23M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Oncopeptides AB's stock has declined approximately 64.71% over the past 52 weeks. The 50-day moving average sits at 0.17, while the 200-day moving average is 0.17.

Over the twelve months ended June 30, 2026, Oncopeptides AB generated 8.60M in revenue and converted that into -19.23M in net income, yielding earnings per share of -0.07. EBITDA reached -17.59M, while operating income came in at -17.59M.

As of June 30, 2026, Oncopeptides AB holds 14.23M in cash and equivalents against 12.20M in total debt, resulting in a net debt position of -2.03M. Total book value stands at 2.25M, with working capital of 13.85M providing operational flexibility.

Oncopeptides AB produced -16.45M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Oncopeptides AB posted a gross margin of 96.40, reflecting its pricing power and cost economics. The operating margin of -204.46 and net profit margin of -223.55 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -38.32: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 11.12, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Oncopeptides AB shareholders.

Oncopeptides AB's most recent stock split took place on February 25, 2026 with a 117:124 split ratio.